{
  "abstract": "Long-term survivors of endometrial cancer face competing risks from cancer and other conditions, but how these risks evolve remains uncertain. We conducted a population-based retrospective cohort study of 255,104 women who underwent hysterectomy-based definitive surgery for endometrial cancer in the Surveillance, Epidemiology, and End Results Program (2000–2021). Cause-specific cumulative incidence was estimated using Aalen–Johansen methods. Crossover was the earliest month when composite non-endometrial mortality (cardiovascular, other malignant cancer, or other non-cancer death) exceeded endometrial cancer-specific mortality and remained higher for 12 months. During a median follow-up of 8.2 years, 62,347 deaths occurred. Endometrial cancer mortality was 6.2%, 7.1%, and 7.4% at 5, 10, and 15 years, compared with 5.3%, 16.6%, and 28.3% for composite non-endometrial mortality. Crossover occurred at 5.6 years (95% confidence interval, 5.4–5.8) overall but was not reached within 15 years for stage III/IV disease or chemotherapy recipients. Among 10-year survivors, subsequent 5-year mortality was 0.4% from endometrial cancer and 15.3% from non-endometrial causes; cardiovascular mortality remained elevated relative to U.S. female rates (standardized mortality ratio, 1.21; 95% confidence interval, 1.16–1.26). These findings support integrated cardiovascular and metabolic risk management from diagnosis alongside individualized, guideline-concordant oncologic surveillance.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "name": "Ruicong Wang"
    },
    {
      "name": "Chuanjia Guo"
    },
    {
      "name": "Fang Tong"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/etk3n4y41ana0.bib",
  "cited_by": 0,
  "doi": "10.1038/s41598-026-71645-5",
  "fulltext_url": null,
  "id": "etk3n4y41ana0",
  "issns": [
    "2045-2322"
  ],
  "landing_url": "https://www.nature.com/articles/s41598-026-71645-5",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2729|Endometrial and Cervical Cancer Treatments"
    ]
  ],
  "openalex": "W7215059697",
  "pdf_url": "https://www.nature.com/articles/s41598-026-71645-5_reference.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "Springer Science and Business Media LLC",
  "ris": "https://research.draconitic.com/paper/etk3n4y41ana0.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:19Z",
      "native_id": "10.1038/s41598-026-71645-5",
      "source": "crossref",
      "url": "https://www.nature.com/articles/s41598-026-71645-5"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2729|Endometrial and Cervical Cancer Treatments",
      "subfield": "reproductive-child"
    }
  ],
  "title": "Cumulative-incidence crossover and conditional mortality after definitive surgery for endometrial cancer: a population-based competing-risk analysis",
  "title_text": "Cumulative-incidence crossover and conditional mortality after definitive surgery for endometrial cancer: a population-based competing-risk analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:19Z",
  "url": "https://research.draconitic.com/paper/etk3n4y41ana0",
  "venue": "Scientific Reports",
  "versions": []
}